A Big Deal: Strategic Rejuvenation for Post-Pandemic Realities

18 Pages

This paper discusses that M&A remains vital but has shifted from mega‑mergers to bolt‑on deals and partnerships as biopharma moves from primary care to specialty therapies. Post‑pandemic headwinds like loss of exclusivity and underperforming launches make strategic deal making crucial. It reports that pipelines for cell, gene and RNA therapies have tripled and deal activity has surged across digital and next‑generation biotherapeutics. Success demands strategic clarity, efficient processes, broad networks, non‑financial differentiators and early post‑deal planning.

Join for free to read

White Paper Post-Pandemic Networking: Enabling the Work-From-Anywhere…

White Paper Franchisee training: Consistency within complexity, post-pandemic

White Paper Communication in a Post-Pandemic Workplace

Case Study The Post-Pandemic Higher Ed Classroom

More from IQVIA

White Paper Riding Out the Storm: The Future of Post-Pandemic Customer…

Vendor Sheet The Case for True Omnichannel Engagement Continues to Grow…

White Paper SEA Pharmacy Retail Playbook: Market-Shaping Factors for…

Infographic How to Battle the Big Squeeze

White Paper

A Big Deal: Strategic Rejuvenation for Post-Pandemic Realities

A Big Deal: Strategic Rejuvenation for Post-Pandemic Realities

You Might Also Like

More from IQVIA